Biotech Values

[DewDiligence]

>If you wanted to promote anticoagulation, you might think of partially inhibiting FVIII.<

This is exactly what BioInvent and ThromboGenics are trying to do with TB-402, but it’s a novel—and high-risk—approach. It’s tantamount to inducing a mild, artificial state of hemophilia-A while hoping to avert the major-bleeding events typical of more severe manifestations of the disorder.